KA/EN
Register
Medicines reference
Search
Search
Product

Purevax RCP

Favourites

Feline herpesvirus + Feline calicivirus + Feline parvovirus · Boehringer Ingelheim Animal Health France SCS

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Cat Cat 0.5 ml
Reconstitute with the 0.5 ml solvent presentation and inject one dose subcutaneously. Give the first dose from 8 weeks and the second 3-4 weeks later; delay the primary course until 12 weeks when high maternal antibody is expected. First revaccination is one year after the primary course, then at intervals up to 3 years. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Injection-site reactions, transient apathy, anorexia or hyperthermia and hypersensitivity can occur.
 · two-dose primary series, then revaccination according to the SPC schedule		 two-dose primary series, then revaccination according to the SPC schedule Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი RCP
№ 40-11
Verified on: 20 Oct 2026
Details: pack, label wording, sources, registration

Purevax RCP, Suspension

lyophilisate and solvent for injection, 0.5 ml dose for cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Purevax RCP

lyophilisate and solvent for injection, 0.5 ml dose for cats
Assessed clinical scopeCat · Full cat label: active immunisation against feline herpesvirus, calicivirus and panleucopenia with the labelled two-dose primary course and revaccination at intervals up to three years · Subcutaneous
Care settingPreventive feline vaccination with examination, cold-chain control, injection-site planning and emergency treatment available
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 40-11 · Verified on 20 Oct 2026

A strong non-adjuvanted feline core option with exact regulatory support and useful long revaccination intervals. Respiratory protection reduces disease rather than eliminating infection, and the kitten course must still account for maternal antibody.

Regulatory and scientific credibility9.0/10

The exact 0.5 ml presentation is registered in Georgia and has a current detailed SPC with transparent strains, potency, schedule, onset, duration, adverse reactions and handling instructions.

Clinical efficacy8.5/10

FPV, FHV and FCV are strongly supported global core targets. Controlled challenge evidence supports meaningful and durable disease reduction, but respiratory components do not provide sterile immunity and maternal antibody can require a later final kitten dose than the label minimum.

Safety and tolerability8.4/10

The non-adjuvanted mixed live/inactivated formulation has a favourable profile in healthy cats, with mainly transient local or systemic reactions; hypersensitivity remains possible and use throughout pregnancy or lactation is contraindicated.

Clinical practicality8.4/10

The fixed 0.5 ml SC dose and post-first-booster intervals up to three years are practical; reconstitution, immediate use, cold chain and guideline-concordant kitten scheduling require routine discipline.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Vaccinate healthy cats only; do not use in hypersensitivity to a component.
  • Do not use during pregnancy or lactation.
  • When high maternal antibody is expected, delay the primary course until 12 weeks and still complete a guideline-concordant kitten series.
  • FCV and FHV protection reduces clinical disease but does not reliably prevent all infection or viral shedding.
  • Hypersensitivity can require immediate treatment; monitor transient injection-site, febrile, appetite and activity changes.
  • Use other vaccines on the same day only where the exact combination is supported; never mix unless expressly authorised.
  • Reconstitute only with the supplied 0.5 ml solvent, use promptly, maintain the cold chain and do not freeze.
Assessment sources
  1. VMD SPC 20262026
  2. WSAVA vaccination 20242024
  3. AAHA/AAFP feline vaccination 20202020
  4. Purevax three-year challenge2015
  5. FCV comparative challenge 20172017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Feline herpesvirus4.9 log10 CCID50/dose Feline calicivirus2 ELISA U/dose Feline parvovirus3.5 log10 CCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer (register)
SCS Boehringer Ingelheim Animal Health France SCS, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1315, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი RCP
№ 40-11
Verified on: 20 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
0.5 ml
Reconstitute with the 0.5 ml solvent presentation and inject one dose subcutaneously. Give the first dose from 8 weeks and the second 3-4 weeks later; delay the primary course until 12 weeks when high maternal antibody is expected. First revaccination is one year after the primary course, then at intervals up to 3 years. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Injection-site reactions, transient apathy, anorexia or hyperthermia and hypersensitivity can occur.
 Cat Any weight Subcutaneous two-dose primary series, then revaccination according to the SPC schedule
VMD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Purevax RCP - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026

Feline herpesvirus: No dose supported by a publicly verifiable source yet

Feline calicivirus: No dose supported by a publicly verifiable source yet

Feline parvovirus: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (1 more) Hide additional products

Same active ingredients 1

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗